Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants
Recruiting
N/A
Interventional Study
Pertussis
Diphtheria
Tetanus
Haemophilus Influenzae Type B Infection
Polio
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 19 Months – 22 Months
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 785 (estimated)
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main purpose of this study is to evaluate immune persistence at 30 and 36 Months of Age and Pertussis Breakthrough Infections between 19 and 36 Months of Age following two regiments of DTaP-IPV/Hib Pentavalent Vaccine in Healthy 2-Month-Old Infants and Children in China.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- (1)Received 4 doses of DTaP-IPV/Hib pentavalent vaccines (2) Obtained consent from the participant's caregiver and sign an informed consent form
Exclusion Criteria:
-(1) Diagnosed by a physician with a coagulation abnormality (e.g., coagulation factor deficiency, coagulopat…
Contacts